Staging laparoscopy for radiographically non-metastatic pancreatic ductal adenocarcinoma: cytology-driven upstaging and the SENDAI-SL risk-enrichment score
BJS Open · 03.11.2026 · 10 (6)
DOI: 10.1093/bjsopen/zrag176 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJS Open, online erschienen am 04.11.2026. Verfasst von Daisuke Douchi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Neoplasm Staging, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Laparoscopy. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cross-sectional imaging may miss occult metastatic disease in pancreatic ductal adenocarcinoma and cannot detect positive peritoneal lavage cytology. This study quantified the yield of staging laparoscopy (SL) with routine lavage cytology and developed the SENDAI-SL score for risk-based prioritization.
Methods
Consecutive patients with radiographically non-metastatic pancreatic ductal adenocarcinoma who underwent SL at one centre from January 2013 to June 2025 were analysed retrospectively. SL positivity was defined as liver metastasis, macroscopic peritoneal metastasis, and/or positive cytology. Multivariable logistic regression identified predictors; internal validation used 2000 bootstrap resamples.
Results
Of 504 patients, 141 (28.0%) had positive SL. Positivity rates were 21.3%, 16.0%, 32.3%, and 41.7% in resectable, borderline resectable with portal vein involvement, borderline resectable with arterial involvement, and unresectable locally advanced disease, respectively. Gross liver or peritoneal metastases were detected in 51 patients (10.1%); cytology was positive in 125 (24.8%) and the sole finding in 90 of 141 positive procedures (63.8%). Among 499 patients with quantifiable serum carbohydrate antigen 19-9, unresectable locally advanced disease, body and/or tail location, tumour size ≥ 37 mm, and serum carbohydrate antigen 19-9 ≥ 180 U/ml were independently associated with SL positivity. The model's area under the receiver operating characteristic curve was 0.732 (optimism-corrected, 0.718). Score-specific positivity ranged from 8.6% to 83.3%. A score ≥ 2 prioritized 149 patients; 74 (49.7%) were positive, capturing 52.9% (74 of 140) of positives in the analysis cohort.
Conclusions
SL upstaged 28.0% of patients, predominantly through cytology-only disease. The SENDAI-SL score may support prioritization when resources are limited but requires external validation and should not justify omitting SL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
ORCID-Profile: Daisuke Douchi
Zitieren
APA
Douchi, D., Yoshimachi, S., Rikiyama, N., Ando, M., Umino, Y., Sato, H., Shimura, M., Inoue, K., Iseki, M., Aoki, S., Miura, T., Maeda, S., Ishida, M., Mizuma, M., Masamune, A., & Unno, M. (2026). Staging laparoscopy for radiographically non-metastatic pancreatic ductal adenocarcinoma: cytology-driven upstaging and the SENDAI-SL risk-enrichment score. BJS Open, 10(6). https://doi.org/10.1093/bjsopen/zrag176
Vancouver
Douchi D, Yoshimachi S, Rikiyama N, Ando M, Umino Y, Sato H, et al. Staging laparoscopy for radiographically non-metastatic pancreatic ductal adenocarcinoma: cytology-driven upstaging and the SENDAI-SL risk-enrichment score. BJS Open. 2026;10(6). doi:10.1093/bjsopen/zrag176
BibTeX
@article{Douchi2026,
author = {Douchi, Daisuke and Yoshimachi, Shingo and Rikiyama, Naoki and Ando, Mika and Umino, Yuichiro and Sato, Hideaki and Shimura, Mitsuhiro and Inoue, Koetsu and Iseki, Masahiro and Aoki, Shuichi and Miura, Takayuki and Maeda, Shimpei and Ishida, Masaharu and Mizuma, Masamichi and Masamune, Atsushi and Unno, Michiaki},
title = {Staging laparoscopy for radiographically non-metastatic pancreatic ductal adenocarcinoma: cytology-driven upstaging and the SENDAI-SL risk-enrichment score},
journal = {BJS Open},
year = {2026},
volume = {10},
number = {6},
doi = {10.1093/bjsopen/zrag176}
}
EUVIMED